Advances in Urological Cancer: Innovative Therapies and Biomarkers
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 May 2026 | Viewed by 16
Special Issue Editor
Interests: prostate cancer; urological cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue focuses on cutting-edge research in urological oncology, emphasizing prostate, urothelial, and kidney cancers. It features innovative therapeutic strategies, novel biomarkers for detection and prognosis, and translational studies bridging bench to bedside. Contributions explore immunotherapy, targeted therapies, liquid biopsies, and AI-driven diagnostics. Guest Editor Dr. Hiroshi Yaegashi’s work on early dynamic changes in albumin and the systemic immune-inflammation index (SII) (ΔAlb + ΔSII), which may have the potential to serve as predictors of progression-free survival in cabozantinib-treated mRCC after immune checkpoint inhibitor (ICI) therapy highlights clinical relevance. This issue aims to accelerate precision medicine in urological cancers.
Dr. Hiroshi Yaegashi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urological oncology
- urothelial cancer
- prostate cancer
- renal cancer
- biomarkers
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
